initiation of contractile force in arterial smooth muscle (SM) is believed to be regulated by the intracellular Ca 2ϩ concentration and SM myosin type II phosphorylation. We tested the hypothesis that SM myosin type II operates as a molecular motor protein in electromechanical, but not in protein kinase C (PKC)-induced, contraction of small resistancesized cerebral arteries. We utilized a SM type II myosin heavy chain (MHC) knockout mouse model and measured arterial wall Ca 2ϩ concentration ([Ca 2ϩ ]i) and the diameter of pressurized cerebral arteries (30-100 m) by means of digital fluorescence video imaging. Intravasal pressure elevation caused a graded [Ca 2ϩ ]i increase and constricted cerebral arteries of neonatal wild-type mice by 20-30%. In contrast, intravasal pressure elevation caused a graded increase of [Ca 2ϩ ]i without constriction in (Ϫ/Ϫ) MHC-deficient arteries. KCl (60 mM) induced a further [Ca 2ϩ ]i increase but failed to induce vasoconstriction of (Ϫ/Ϫ) MHC-deficient cerebral arteries. Activation of PKC by phorbol ester (phorbol 12-myristate 13-acetate, 100 nM) induced a strong, sustained constriction of (Ϫ/Ϫ) MHC-deficient cerebral arteries without changing [Ca 2ϩ ]i. These results demonstrate a major role for SM type II myosin in the development of myogenic tone and Ca 2ϩ -dependent constriction of resistance-sized cerebral arteries. In contrast, the sustained contractile response did not depend on myosin and intracellular Ca 2ϩ but instead depended on PKC. We suggest that SM myosin type II operates as a molecular motor protein in the development of myogenic tone but not in pharmacomechanical coupling by PKC in cerebral arteries. Thus PKC-dependent phosphorylation of cytoskeletal proteins may be responsible for sustained contraction in vascular SM.
CONTRACTION OF SMOOTH MUSCLE (SM) is based on a sliding-filament mechanism similar to that of striated muscle. The SM contraction is regulated by electromechanical as well as by pharmacomechanical coupling mechanisms. Excitation-contraction coupling by electromechanical mechanisms depends on the membrane potential and Ca 2ϩ influx through voltage-gated Ca 2ϩ channels in the plasma membrane, such as L-type Ca 2ϩ channels (38) . In small arteries, membrane depolarization from Ϫ50 to Ϫ40 mV increases external Ca 2ϩ influx, leading to an increase in global intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) and subsequent activation of the contractile machinery. Lowering [Ca 2ϩ ] i reverses contraction (17) . Conclusively, force produced by electromechanical coupling depends on Ca 2ϩ ions surrounding the contractile filaments. In contrast, Ca 2ϩ ions are believed to play a minor role in pharmacomechanical coupling. The activation of protein kinase C (PKC) and other intracellular enzymes seems to play a key role in force production by many vasoconstrictor hormones (38) .
SM contraction exhibits several distinct properties that are not present in skeletal muscle. For example, the regulation of crossbridges interaction in SM contraction by Ca 2ϩ seems to be more complicated than in striated muscle (32) . Accordingly, pharmacomechanical coupling of SM can be induced in Ca 2ϩ -free external solutions, suggesting additional, Ca 2ϩ -independent pathways of SM contraction (8) . We used the SM myosin type II heavy chain (MHC) knockout mouse to provide evidence that SM myosin type II operates as the molecular motor protein for depolarization-induced, Ca 2ϩ -dependent constriction of small cerebral arteries, i.e., in electromechanical coupling. In addition, we show that PKC-dependent, sustained constriction does not depend on intracellular Ca 2ϩ and SM myosin type II. We suggest that this myosin-independent contractile pathway may play a major role in pharmacomechanical coupling of small, resistancesized arteries.
MATERIALS AND METHODS
Cerebral arteries. Cerebral arteries were obtained from neonatal (ϩ/ϩ) and (Ϫ/Ϫ) SM-MHC-deficient mice genotyped after the experiment (30) . After decapitation, the brain was removed and quickly transferred to cold (4°C), oxygenated (95% O 2/5% CO2) physiological salt solution (PSS) of the following composition (in mM): 119 NaCl, 4.7 KCl, 25 NaHCO 3, 1.2 KH2PO4, 1.6 CaCl2, 1.2 MgSO4, 0.03 EDTA, and 11 glucose. Thereafter, the cerebral arteries were dissected from the brain and placed in cold PSS. Connective tissue was removed. For measurements of intracellular arterial wall [Ca 2ϩ ]i, the vessels were incubated with the Ca 2ϩ -sensitive indicator fura 2-AM (5 M) and pluronic acid (0.005%; wt/vol) for 45 min at room temperature in oxygenated PSS. After loading with fura 2-AM, the arteries were cannulated in a chamber on glass canulas on both sides, allowing an application of hydrostatic pressure to the vessel (for details, see Refs. 6, 9, 26, 29) . [Ca 2ϩ ]i and diameter were measured simultaneously by using a conventional spectrometer (dm3000; SPEX, Edison, NJ) and a videomicroscopic system (Nikon Diaphot, Dü sseldorf, Germany) connected to a personal computer with appropriate software for detection of changes of vessel diameter (TSE, Bad Homburg, Germany) (for calibration and details, see Ref. 9) . All experiments were performed at 37°C.
Materials and statistics. Fura 2-AM was purchased from Molecular Probes (Eugene, OR). Stock solutions (0.25 mM) of fura 2-AM were made using DMSO as the solvent. All salts and drugs were obtained from Sigma Aldrich (Deisenhofen, Germany) or Merck (Darmstadt, Germany). High external potassium solutions were made by iso-osmotic substitution of NaCl with KCl in the PSS. All values are given as means Ϯ SE. For group comparisons, paired and unpaired Student' s t-tests or nonparametric Wilcoxon tests were used as appropriate. A value of P Ͻ 0.05 was considered statistically significant; n ϭ number of arteries tested.
RESULTS
Electromechanical coupling. We first measured intracellular arterial wall [Ca 2ϩ ] i and vessel diameter of isolated cerebral arteries of (ϩ/ϩ) and (Ϫ/Ϫ) SM-MHC mice at an intravasal pressure of 10 mmHg. The cerebral arteries of (ϩ/ϩ) and (Ϫ/Ϫ) SM-MHC mice showed no macroscopic differences, for instance in diameter or branching. Figure 1 shows that resting intracellular [Ca 2ϩ ] i (ϳ100 nM) and diameter (ϳ80 m) were not different (P Ͻ 0.05). In cerebral arteries of (ϩ/ϩ) SM-MHC mice, an increase in intravasal pressure from 30 to 60 mmHg induced an increase in [Ca 2ϩ ] i and decreased vessel diameter (myogenic constriction) by 20 m (Figs. 2B and 4B; P Ͻ 0.05). To evaluate electromechanical coupling in cerebral arteries of (ϩ/ϩ) SM-MHC mice, high concentrations of external K ϩ (60 mM) were applied to the arteries and evoked an increase in [Ca 2ϩ ] i to ϳ1,000 nM and an additional 20% constriction in the vessels of (ϩ/ϩ) SM-MHC mice, compared with controls (Figs. 2B and 4B; P Ͻ 0.05). In contrast, cerebral arteries of (Ϫ/Ϫ) SM-MHC mice did not develop myogenic constriction when intravascular pressure was increased to 30 or to 60 mmHg (Figs. 3B and 4A). Instead, the vessel diameter was "passively" increased by these maneuvers by 15 to 20% ( Fig. 4A ; P Ͻ 0.05). However, the stepwise increase in intravascular pressure from 10 to 60 mmHg induced a graded increase in [Ca 2ϩ ] i up to 200 nM (P Ͻ 0.05). High concentrations of external K ϩ (60 mM) were applied to the arteries of (Ϫ/Ϫ) SM-MHC mice to test whether or not the electromechanical coupling in these arteries was functional. Application of 60 mM KCl to arteries of (Ϫ/Ϫ) SM-MHC mice evoked an increase in [Ca 2ϩ ] i to ϳ1,000 nM (Figs. 3B and 4A; P Ͻ 0.05). However, this maneuver did not constrict the vessels (Figs. 3B and 4A; P Ͻ 0.05). These findings indicate that pressure-induced and membrane potential-dependent Ca 2ϩ influx mechanisms are intact in arteries of (Ϫ/Ϫ) SM-MHC mice (Fig. 3B ). However, in sharp contrast to arteries of (ϩ/ϩ) SM-MHC mice, Ca 2ϩ -dependent, electromechanical coupling was not functional in cerebral arteries lacking SM-MHC (Fig. 3B) .
PKC-induced constriction. We next tested the hypothesis that PKC induces pharmacomechanical coupling in cerebral arteries. In the presence of external Ca 2ϩ , the PKC activator phorbol 12-myristate 13-acetate (PMA, 100-500 nM) induced a strong constriction of arteries of (ϩ/ϩ) SM-MHC mice (Figs. 5B and 7B; P Ͻ 0.05). PMA did not increase [Ca 2ϩ ] i (Figs. 5B and 7B; P Ͼ 0.05). The SM constriction induced by PMA was rapid and reached the maximum (ϳ50-60% constriction) after 2 min (half-activation time of contraction ϳ99 s; Fig. 5B ). This PMA effect was not attenuated in both nominal Ca 2ϩ -free and Ca 2ϩ -buffered [5 mM N-(2-hydrohyethyl)ethylenediamine-N,N',N'-triacetic acid (HEDTA)] solutions (P Ͼ 0.05). These find- ]i (arbitrary units in %; 100%) and steady-state vessel diameter (100%) obtained with 10 mmHg before administration of 30 mmHg, 60 mmHg, or 60 mM KCl (n Ն 12). A: arteries of (Ϫ/Ϫ) SM-MHC mice did not develop the myogenic response or constricted to 60 mM KCl. B: arteries of (ϩ/ϩ) SM-MHC mice showed a reduced diameter in response to increased intravascular tone or KCl. ings indicate that PKC activation induces a fast, sustained, and relatively Ca 2ϩ -independent induced constriction of cerebral arteries of (ϩ/ϩ) SM-MHC mice.
In contrast, PMA (100-500 nM) evoked a delayed constriction of (Ϫ/Ϫ) MHC-deficient arteries by ϳ30% ] i to ϳ1 M in cerebral arteries of (Ϫ/Ϫ) SM-MHC mice (P Ͻ 0.05) but did not induce further vessel constriction (P Ͼ 0.05). Cerebral artery constriction induced by stimulation of PMA was completely inhibited by a 10-min preincubation with calphostin C (100 nM; data not shown; n ϭ 3).
DISCUSSION
The mechanisms that lead to sustained SM contraction that occurs in arterial vasospasm and arterial hypertension remain unknown (39) . We used the SM-MHC-deficient (Ϫ/Ϫ) mouse to characterize excitationcontraction coupling in myogenic cerebral arteries. Our data suggest that SM-MHC type II operates as a molecular motor protein in electromechanical coupling but not in pharmacomechanical coupling mediated by PKC of cerebral arteries. Electromechanical coupling in cerebral arteries of (ϩ/ϩ) and (Ϫ/Ϫ) SM-MHC mice was tested by elevating intravascular pressure to induce myogenic tone and by application of high potassium chloride (60 mM KCl) (1, 2, 13, 22, 28) . Elevated intravasal pressure (60 mmHg) and application of 60 mM KCl increased [Ca 2ϩ ] i and reduced vessel diameter in cerebral arteries of (ϩ/ϩ) SM-MHC mice. In contrast, arteries of (Ϫ/Ϫ) SM-MHC mice did not develop myogenic tone but nevertheless showed normal Ca 2ϩ transport regulation. Because of normal pressure-and Ն 12) . A: application of phorbol ester evoked a ϳ40% constriction of arteries of (Ϫ/Ϫ) SM-MHC mice. The phorbol ester evoked constriction was maintained in Ca 2ϩ -free or Ca 2ϩ -buffered bath solution (A). B: application of phorbol ester evoked in arteries of (ϩ/ϩ) SM-MHC mice a ϳ55% vasoconstriction. The phorbol ester induced constriction did not depend on extracellular calcium. and SM myosin type II play a major regulatory role in electromechanical coupling. In contrast, pharmacomechanical coupling induced by protein kinase C activation is relatively insensitive to changes of membrane potential and [Ca 2ϩ ]i. We suggest that this pathway is mediated by protein kinase C-induced phosphorylation of an unknown intracellular motor protein. Possible candidates are a cytoskeletal protein or nonidentified myosin isoforms.
] i increases in arteries of (Ϫ/Ϫ) SM-MHC mice, we assume that the initial step of electromechanical coupling in SM is functional in these arteries. However, the lack of SM contraction indicates that the contraction signal could not be converted into force by the contractile apparatus. The results indicate that other myosin isoforms could not assume force production in the absence of SM myosin type II. This finding is contrary to the suggestions by Morano et al. (30) , who studied the urinary bladder of (Ϫ/Ϫ) SM-MHC mice (30) . They reported that SM strips from urinary bladder of (Ϫ/Ϫ) MHC mice showed a sustained contraction after high doses of KCl (60 mM). We failed to observe a fast initial (phase 1) or a delayed (phase 2) contraction in cerebral artery preparations, as reported for urinary bladder (30) . Morano et al. (30) suggested that nonmuscle myosin assumed the function of SM myosin type II to induce contraction in (Ϫ/Ϫ) SM myosin urinary bladder. However, because we did not observe contraction in (Ϫ/Ϫ) SM-MHCdeficient mice, it is possible that the complete myosinactin-dependent contractile machinery is not functional in vascular SM of (Ϫ/Ϫ) SM-MHC-deficient cerebral arteries. Moreover, the data demonstrate that SM type II myosin operates a molecular motor protein in the development of myogenic tone and electromechanical coupling of cerebral arteries (Fig. 8) .
PKC-induced arterial constriction of MHC-deficient mice. Many hormonal vasoconstrictors activate PKC and, thereby, induce "pharmacomechanical" contraction of arterial SM (10) . Analysis of PKC activation in SM revealed that during this process, some PKC isoforms translocate to the membrane (11, 12, 19, 20, 21, 24, 37) and are involved in the Ca 2ϩ sensitization of the intact SM (3, 14, 25, 34) . As shown by others, PKC activation induces a sustained arterial SM contraction in arteries expressing SM-MHC type II (3, 5, 16, 31, 36) with a slight (35) or no increase in [Ca 2ϩ ] i (15, 40) . We observed also that lowering extracellular Ca 2ϩ , by using nominal Ca 2ϩ -free bath solution or strong buffered Ca 2ϩ -free bath solution, did not influence PKC-induced contraction of wild-type cerebral arteries. Moreover, our results show that the PKC-induced vessel constriction is still inducible in arteries of (Ϫ/Ϫ) SM-MHC mice. Thus we suggest that PKC-induced contraction in cerebral arteries of (ϩ/ϩ) SM-MHC mice may involve two components. The first is a SM myosin type II-mediated contraction with a fast onset, within 2 min after PKC stimulation. The second is a contraction mediated by a molecular motor protein other than SM myosin type II, namely a non-SM-myosin type II motor protein (possibly nonmuscle myosin). The latter molecular motor protein is turned on by PKC in cerebral arteries with a slow onset, ϳ15 min after PKC stimulation. According to this model, we observed only the delayed non-SM myosin type II motor protein-mediated constriction with a slow onset (15 min) in arteries of (Ϫ/Ϫ) SM-MHC mice. Extracellular Ca 2ϩ is not necessary to maintain this contractile mechanism.
In this context, it is noteworthy that PKC activation leads to changes in the cell cytoskeleton in a variety of cells and may represent an important regulator of cytoskeletal functions (18) . Platts et al. (33) showed that the microtubule network is involved in arterial SM contraction. Using pharmacological tools, they induced changes in the vascular SM cell microtubular network and observed constriction of the vessel without changes in [Ca 2ϩ ] i . These effects were not dependent on the endothelium (33) . Thus PKC-dependent phosphorylation of cytoskeletal proteins may be responsible for sustained contraction in vascular SM, including those in cerebral arteries of (Ϫ/Ϫ) SM-MHC mice (Fig. 8) . The cytoskeleton may interact with novel, still unidentified cytoplasmic proteins to produce contraction. Such proteins could serve as a substrate for PKC. They should be tightly associated with the cytoskeleton, and binding should be possibly Ca 2ϩ independent. A short protein with these attributes was recently found in SM (4, 7, 27) .
In conclusion, we provide indirect evidence for a novel molecular motor protein that is able to induce sustained, Ca 2ϩ -independent contraction of arterial SM. This nonmyosin type II motor protein can be activated by PKC and seems to play a major role in pharmacomechanical coupling of arterial SM. Further, SM myosin type II operates as a key element in the development of myogenic tone and electromechanical coupling of small, resistance-sized cerebral arteries. Pharmacomechanical coupling mediated by a nonmyosin type II is of interest in various pathophysiological conditions, including hypertension, coronary vasospasm, and migraine. It remains to characterize the molecular motor, and further studies are needed to clarify this point.
